Nectar Lifesciences Quarterly Results
Nectar Lifesciences quarterly results. In Sept 2026, Nectar Lifesciences (NECLIFE) reported revenue ₹14 Cr and net profit ₹3 Cr. View Nectar Lifesciences 52-week for the annual high/low range and current price position.
NECLIFE Quarterly Results — Revenue, Profit & EPS Highlights
Nectar Lifesciences latest quarter revenue, net profit, EPS and QoQ/YoY growth rates. For annual financials, live price and key ratios, visit Nectar Lifesciences share price chart.
- Revenue of ₹14 Cr in Sept 2026 (+133.3% vs Mar 2026)
- Net Profit of ₹3 Cr in Sept 2026 (+104.4% vs Mar 2026, +101.7% vs Sept 2025)
- EBITDA of ₹7 Cr in Sept 2026 (+108.4% vs Mar 2026)
- Operating Margin of -75200.0% in Sept 2026
- Earnings Per Share of ₹0.14 in Sept 2026 (+104.1% vs Mar 2026)
Nectar Lifesciences Quarterly Results — Revenue, EBITDA, Net Profit & EPS
NECLIFE quarterly revenue, expenses, EBITDA, net profit, EPS and operating margin with QoQ and YoY comparison.
| Metric | Sept 2026 | Mar 2026 | Jun 2026 | Sept 2025 | Mar 2025 | QoQ | YoY |
|---|---|---|---|---|---|---|---|
| Revenue (₹ Cr) | 14 | 6 | 3 | 0 | 0 | 133.3% | - |
| Net Profit (₹ Cr) | 3 | -68 | -15 | -176 | -130 | - | - |
| EBITDA (₹ Cr) | 7 | -83 | -25 | -176 | -130 | - | - |
| EPS (₹) | 0.14 | -3.38 | -0.79 | -7.85 | -5.80 | - | - |
| Operating Margin (%) | -75200.0% | 0.0% | -277000.0% | 0.0% | 0.0% | - | - |
NECLIFE Share Price Trend — 1-Year Movement Across Quarterly Results
Nectar Lifesciences 1-year share price in ₹ overlaid with quarterly earnings dates — NSE/BSE closing prices. Also explore NECLIFE share price charts to track price trends across different timeframes.
Revenue Trend (₹ Cr)
Net Profit Trend (₹ Cr)
Operating Margin Trend (%)
NECLIFE vs Healthcare Peers — Quarterly Revenue, Profit & Market Cap
Nectar Lifesciences latest quarter revenue and net profit vs Healthcare competitors — market cap, price and earnings comparison.
| Company Latest Quarter | Market Cap (₹ Cr) | Price (₹) | Revenue (₹ Cr) | Net Profit (₹ Cr) | Rev QoQ % | Rev YoY % | Profit Margin % | P/E Ratio |
|---|---|---|---|---|---|---|---|---|
|
Sun Pharmaceutical
Sept 2026 |
₹451,074.97 Cr | 1884.9 | 16,617 | 1,995 | +10.6% | - | 12.0% | 227.1 |
|
Divis Laboratories
Sept 2026 |
₹294,139.19 Cr | 11180.5 | 3,770 | 1,127 | +26.3% | - | 29.9% | 263.1 |
|
Torrent Pharmaceuti…
Mar 2026 |
₹188,719.51 Cr | 4689.5 | 4,111 | 364 | +27.7% | +42.2% | 8.9% | 407.4 |
|
Apollo Hospitals
Sept 2026 |
₹132,281.88 Cr | 9200.0 | 7,673 | 660 | +15.2% | - | 8.6% | 209.9 |
|
Laurus Labs
Sept 2026 |
₹125,946.78 Cr | 2294.6 | 2,219 | 436 | +21.7% | - | 19.6% | 280.9 |
QoQ: Quarter over Quarter • YoY: Year over Year
All amounts in ₹ Crores